Trudie Lobban MBE
Founder & CEO – Arrhythmia Alliance and AF Association
The recent decision by the National Institute for Health and Care Excellence (NICE) to approve leadless pacemakers for ventricular pacing across the NHS marks an important evolution in cardiac care.
Leadless pacemakers could meaningfully improve the lives of thousands living with bradyarrhythmia. These conditions, defined by abnormally slow heart rhythms, may seem deceptively simple but can cause debilitating symptoms such as fatigue, dizziness, fainting and breathlessness.
Left untreated, they place patients at increased risk of serious complications. With roughly one in every 1,000 people affected, access to safer and more advanced treatment options is crucial.
Leadless pacemakers: a significant step forward in technology and patient experience
Unlike traditional pacemakers — which require a surgical pocket in the chest and wires threaded through veins into the heart — leadless devices are self-contained and implanted directly into the heart without the need for leads. Their miniature design allows them to be delivered through a small 1 cm incision using a vein in the groin or neck, a stark contrast to the 5-6 cm chest incision typical of conventional systems.
NICE’s review confirms what early adopters have observed: these devices aren’t only safe and effective but may also offer quality‑of‑life improvements. By eliminating surgical pockets and leads, they reduce the risk of infection and device-related complications, an especially important advantage for patients with limited venous access, prior pacemaker infections or other clinical complexities. In many cases, leadless pacemakers may become the preferred option rather than the alternative.
By eliminating surgical pockets and leads, they reduce the risk of infection and device-related complications
Innovation matched with accountability
Equally important is NICE’s emphasis on ensuring these procedures are performed by trained cardiac teams in specialist centres, with patient outcomes monitored nationally. This commitment to oversight and long-term evaluation ensures that innovation is matched with accountability.
For many patients, access to leadless pacemakers will mean more than just a safer procedure. It opens the door to returning to work sooner, maintaining independence and actively participating in daily life without the limitations often associated with traditional device implantation. With this approval, the NICE isn’t just adopting new technology; it’s embracing a future where cardiac care is less invasive, more personalised and ultimately more empowering.
